RecallRadar

FDA Device recall Z-1690-2018

ADVIA Centaur¿ HBc IgM

On 2018-05-16 the FDA classified a Class II recall of ADVIA Centaur¿ HBc IgM by Siemens Healthcare Diagnostics, citing concentrations for the level of biotin that does not interfere is not currently listed in the instruction for use for the Dimension Vista CTNI, Dimension Vista MMB, Dimension Siro….

Read the official FDA Device notice

AgencyFDA Device
Recall numberZ-1690-2018
ClassificationClass II
Statusterminated
Initiated2018-01-02
Published2018-05-16
Last updated2026-09-13 11:54 UTC
CompanySiemens Healthcare Diagnostics
DistributionUS

Product

ADVIA Centaur¿ HBc IgM

Reason

Concentrations for the level of biotin that does not interfere is not currently listed in the instruction for use for the Dimension Vista CTNI, Dimension Vista MMB, Dimension Sirolimus, ADVIA Centaur FOL, ADVIA Centaur aHBcM and the following IMMULITE assays, 3gAllergy Specific IgE, anti-HBc, BR-MA (CA15-3), CEA, Folic Acid, Gastrin, OM-MA (CA125), Thyroglobulin, and Vitamin B12, and these assays are susceptible to interference from biotin.

Identifiers

code_info
ADVIA Centaur¿ HBc IgM; test, hepatitis b (b core, be antigen, be antibody, b core igm); SMN 10308978 Lot codes:…ADVIA Centaur¿ HBc IgM; test, hepatitis b (b core, be antigen, be antibody, b core igm); SMN 10308978 Lot codes: ADVIA Centaur aHBcM Lot # 02437164 14331164 20876164 29394164 81764164 93146164 26976167 39604167 44125167 56754167 67635167 77328167 01396170 07110170 21484170 67103170 86117170 92364170 31751171 33726171 41538171 ***Added 9/11/20*** 10308978 ***Added 11/2/20*** 62572190 ***Added 3/11/21*** 39927194

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:54 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/device/enforcement.json?search=recall_number:%22Z-1690-2018%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.